Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil

Yang P, Ebbert JO, Sun Z, Weinshilboum RM (2006) Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 24:1761–1769 Leonessa F, Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43–73 Harbottle A, Daly AK, Atherton K, Campbell CF (2001) Role of glutathione-S- transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer 92:777–783 Magnarin M, Morelli M, Rosati A, Bartoli F, Candussio L, Giraldi T et al (2004) Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells. Eur J Pharm 483:19–28 Uchiyama-Kokubu N, Watanabe T (2001) Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance. Anti-Cancer Drugs 12:769–779 Pesic M, Markovic JZ, Jankovic D, Kanazir S, Markovic ID, Rakic L, Ruzdijic S (2006) Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother 18(1):66–73 Miraglia E, Viarisio D, Riganti C, Costamagna C, Ghigo D, Bosia A (2005) Na+/H + exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int J Cancer 115:924–929 Pešić M, Andjelković T, Banković J, Marković ID, Rakić L, Ruždijić S (2009) Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/ R). Invest New Drugs 27:99–110 Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshimi S, Tyagi AK, Chan DCF, Agarwal C, Agarwal R (2004) Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor κB-mediated inducibile chemoresistance. Clin Cancer Res 10:8641–8647 Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE (2007) Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 67:3878–3887 Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87(2–3):227–253 Andjelkovic T, Pesic M, Bankovic J, Tanic N, Markovic ID, Ruzdijic S (2008) Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R). Cancer Biol Ther 7(7):1024–1032 Tortora G, di Isernia G, Sandomenico C, Bianco R, Pomatico G, Pepe S, Bianco AR, Ciardiello F (1997) Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res 57:5107–5111 McDaid HM, Johnston PG (1999) Synergistic interaction between paclitaxel and 8-chloro-adenosine 3′, 5′-monophosphate in human ovarian carcinoma cell lines. Clin Cancer Res 5:215–220 Srivastava RK, Srivastava AR, Cho-Chung YS (1998) Synergistic effects of 8-chlorocyclic-AMP and retinoic acid on induction of apoptosis in Ewing’s sarcoma CHP-100 cells. Clin Cancer Res 4(3):755–761 Jankovic D, Pesic M, Markovic J, Kanazir S, Markovic I, Rakic L, Ruzdijic S (2006) The combination of sulfinosine and 8-ClcAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro. Invest New Drugs 24:15–25 Milosevic J, Kanazir S, Medic-Mijacevic L, Pejanovic V, Stokic Z, Konjevic G, Ruzdijic S (2002) Sulfinosine-induced cell growth inhibition and apoptosis in human lung carcinomas in vitro. Invest New Drugs 20:229–240 Srivastava RK, Srivastava AR, Cho-Chung YS (2000) Synergistic effects of 8-ClcAMP and retinoic acids in the inhibition of growth and induction of apoptosis in ovarian cancer cells: Induction of retinoic acid receptor beta. Mol Cell Biochem 204:1–9 Tortora G, Ciardiello F, Pepe S, Tagliaferri P, Ruggiero A, Bianco C, Guarrasi R, Miki K, Bianco AR (1995) Phase I clinical study with 8-chloro-cAMP and evaluation of immunological effects in cancer patients. Clin Cancer Res 1(4):377–384 Scala S, Budillon A, Zhan Z, Cho-Chung YS, Jefferson J, Tsokos M, Bates SE (1995) Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells. J Clin Invest 96:1026–1034 Vilpo J, Koski T, Vilpo L (2000) Calcium antagonists potentiate P-glycoproteinindependent anticancer drugs in chronic lymphocytic leukemia cells in vitro. Haematologica 85:806–813 Revankar GR, Hanna NB, Imamura N, Lewis AF, Larson SB, Finch RA, Avery TL, Robins RK (1990) Synthesis and in vivo antitumor activity of 2-amino-9Hpurine-6-sulfenamide, -sulfinamide, and -sulfonamide and related purine ribonucleosides. J Med Chem 33(1):121–128 Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55 Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN (1990) Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 50:1748–1756 Bösch S, Siavoshian S, Jacquot C, Tomasoni C, Dabouis G, Elanbaloussi Y, Leneel T, More MT, Roussakis C (1997) Correlation between multidrug resistance and the degree of differentiation of non-small-cell bronchopulmonary carcinoma (NSCLC) in vitro and in vivo. Anticancer Res 17(6D):4595–4598 Wong H, Anderson WD, Cheng T, Riabowol KT (1994) Monitoring mRNA expression by polymerase chain reaction: the “primer-dropping” method. Anal Biochem 223:251–258 Gupte RS, Weng Y, Liu L, Lee MYWT (2005) The second subunit of the replication factor C complex (RFC40) and the regulatory subunit (RIα) of protein kinase A form a protein complex promoting cell survival. Cell Cycle 4:323–329 Boik JC, Newman RA (2008) A classification model to predict synergism/antagonism of cytotoxic mixtures using protein-drug docking scores. BMC Pharmacol 8:13 Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68(1):110–118 Berridge M, Lipp P, Bootman M (1999) Calcium signalling. Curr Biol 9:R157–R159 Trompier D, Chang XB, Barattin R, du Moulinet D’Hardemare A, Di Pietro A, Baubichon-Cortay H (2004) Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res 64:4950–4956 Avery TL, Finch RA, Vasquez KM, Radparvar S, Hanna NB, Revanker GR et al (1990) Chemotherapeutic characterization in mice of 2-amino-9-beta-Dribofuranosylpurine-6-sulfinamide (sulfinosine), a novel purine nucleoside with unique antitumor properties. Cancer Res 50:2625–2630